Results season is upon. Listen in for the latest snippets we have picked up plus a summary of our final research reports in January. Our speedy zoom schedule revealed that pharma is investable again. It’s obesity with a larger side-dish of pharma names. Investor sentiment is highest on AstraZeneca, Merck & Co & UCB and lowest on Sanofi, AbbVie and Zealand.